In this interview at ESMO 2018, Dr Yungan Tao speaks about the GORTEC 2004-01 randomised phase III trial which looked at 70 Gy/35 F with conventional radiotherapy versus 75 Gy/35 F with intensity-modulated radiotherapy. Dr Tao explains the results and limitations of the study and how this information adds to the body of evidence to support the use of intensity-modulated radiotherapy for locally advanced head and neck squamous cell carcinomas.
Questions:
1. What is intensity-modulated radiotherapy (IMRT) and what are its advantages compared with conventional radiotherapy? (0:11)
2. What was the rationale for investigating dose escalation of radiotherapy when administered with cisplatin? (0:46)
3. What were the findings of this study? (1:26)
4. What were the limitations of this study? (2:53)
5. How do you expect the role of IMRT to evolve in the future? (3:43)
Speaker disclosures: Yungan Tao has nothing to disclose in relation to this interview.
Filmed at the European Society for Medical Oncology (ESMO) 2018 Congress, Munich, Germany, 19–23 October 2018.
